UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November 5~~December 19, 2007

LIPID SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	~~0-497~~	430-~~0433090~~497	43-0433090
(State or other jurisdiction of incorporation)	~~(Commission File Number)~~	(~~I.R.S~~Commission ~~Employer~~File ~~Identification No.~~Number)	(I.R.S Employer Identification No.)
7068 Koll Center Parkway, Suite 401, Pleasanton, California			94566
(Address of principal executive offices)			(Zip Code)

7068 Koll Center Parkway, Suite 401, Pleasanton, California	94566
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (925) 249-4000

(Former name or former address, if changed since last report.) N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On ~~November 5~~ December 19, 2007, Lipid Sciences, Inc. ~~issued~~announced athe ~~press~~conclusion ~~release~~of enrollment ~~entitled~~of ~~“Lipid~~new ~~Sciences,~~patients ~~Inc.~~in ~~Reports~~the Company’s HDL Therapy Clinical Trial ~~Financial~~currently ~~Results~~being ~~for~~conducted at the ~~Third~~Washington ~~Quarter~~Hospital ~~2007~~Center, Suburban Hospital, and Washington Adventist Hospital.” The Aprincipal ~~copy~~goal of this trial was to demonstrate the ~~press~~safety ~~release~~and isfeasibility ~~furnished~~of the asCompany’s ~~Exhibit~~HDL 99Selective Delipidation process.1 Patients tocurrently ~~this~~enrolled ~~report~~in the trial will have completed their scheduled plasma collection and re-infusion treatments by the end of January 2008.

The information in this Item 2.02, including 99.1 exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. In addition, the information in this Item 2.02 shall not be incorporated by reference into any document filed under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporating language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 Press release entitled “Lipid Sciences, Inc. ~~Reports~~Concludes ~~Financial~~Enrollment ~~Results~~In ~~for~~HDL ~~the~~Therapy ~~Third~~Clinical ~~Quarter 2007~~Trial.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lipid Sciences, Inc.
Date: November 5, 2007	By:	/s/ Sandra Gardiner
Date: December 20, 2007	By:	/s/ Sandra Gardiner
		Sandra Gardiner
		Chief Financial Officer

Filing Compare · LIPID SCIENCES INC/